Calvin

446 posts

2023.04.11

HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

2023.03.20

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update

2022.11.03

Poster Presentations at ASH 2022

2022.10.05

Poster Presentations at SITC 2022

2022.08.22

I-Mab Business and Corporate Updates and Financial Results for 1H 2022

2022.07.25

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update

2022.07.25

I-Mab 2022 R&D Day

2022.07.25

Lemzoparlimab Data Readout at ESMO 2022

2022.07.25

I-Mab Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates

2022.07.25

I-Mab at Bank of America Securities Global Virtual Healthcare Conference